NeuroPace logo

NeuroPaceNASDAQ: NPCE

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 April 2021

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$269.83 M
-44%vs. 3y high
58%vs. sector
-vs. 3y high
-vs. sector
-12%vs. 3y high
98%vs. sector
-52%vs. 3y high
53%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:26:51 GMT
$9.04-$0.05(-0.55%)

Dividend

No data over the past 3 years
$21.06 M$20.90 M
$21.06 M-$5.45 M

Analysts recommendations

Institutional Ownership

NPCE Latest News

What Makes NeuroPace (NPCE) a New Buy Stock
zacks.com18 November 2024 Sentiment: POSITIVE

NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
zacks.com18 November 2024 Sentiment: POSITIVE

The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript
seekingalpha.com12 November 2024 Sentiment: NEUTRAL

NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
zacks.com12 November 2024 Sentiment: POSITIVE

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.

Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
zacks.com28 October 2024 Sentiment: NEUTRAL

NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
globenewswire.com22 October 2024 Sentiment: POSITIVE

MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace Strengthens Management Team with Two Key Appointments
globenewswire.com04 September 2024 Sentiment: POSITIVE

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately.

NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
globenewswire.com27 August 2024 Sentiment: POSITIVE

MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September.

NeuroPace to Participate in Upcoming Healthcare Conferences in September
globenewswire.com22 August 2024 Sentiment: POSITIVE

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA.

NeuroPace: Only For Those With Strong Nerves
seekingalpha.com20 August 2024 Sentiment: POSITIVE

NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. NeuroPace stock is displaying substantial volatility and looks interesting on a highly speculative basis, anticipating wider approval of RNS.

What type of business is NeuroPace?

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

What sector is NeuroPace in?

NeuroPace is in the Healthcare sector

What industry is NeuroPace in?

NeuroPace is in the Medical Devices industry

What country is NeuroPace from?

NeuroPace is headquartered in United States

When did NeuroPace go public?

NeuroPace initial public offering (IPO) was on 22 April 2021

What is NeuroPace website?

https://www.neuropace.com

Is NeuroPace in the S&P 500?

No, NeuroPace is not included in the S&P 500 index

Is NeuroPace in the NASDAQ 100?

No, NeuroPace is not included in the NASDAQ 100 index

Is NeuroPace in the Dow Jones?

No, NeuroPace is not included in the Dow Jones index

When was NeuroPace the previous earnings report?

No data

When does NeuroPace earnings report?

The next expected earnings date for NeuroPace is 05 March 2025